ORIC Logo_RGB.png
ORIC Pharmaceuticals Appoints Lori Kunkel, M.D., to its Board of Directors
June 09, 2020 16:15 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., June 09, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms...
ORIC Logo_RGB.png
ORIC Pharmaceuticals Announces Five Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II
May 27, 2020 06:30 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of...
ORIC Logo_RGB.png
ORIC Pharmaceuticals to Present at the Jefferies 2020 Global Healthcare Conference
May 26, 2020 06:30 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., May 26, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of...
ORIC Logo_RGB.png
ORIC Pharmaceuticals Reports First Quarter 2020 Financial and Operational Results
May 20, 2020 16:15 ET | ORIC Pharmaceuticals
Successful completion of $138.0 million initial public offering; cash and cash equivalents of $204.2 million as of April 30th expected to fund current operating plan into 2023 Lead program ORIC-101...
ORIC Logo_RGB.png
ORIC Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 28, 2020 16:30 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms...
ORIC Logo_RGB.png
ORIC Pharmaceuticals Presents Preclinical Data on CD73 Inhibitor at the American Association for Cancer Research (AACR) Virtual Annual Meeting
April 27, 2020 16:30 ET | ORIC Pharmaceuticals
Orally bioavailable small molecule CD73 inhibitors reverse immunosuppression by blocking adenosine production Internal research program led to discovery of clinical candidate ORIC-533, which in...
ORIC Logo_RGB.png
ORIC Pharmaceuticals Announces Pricing of Initial Public Offering
April 23, 2020 20:56 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., April 23, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms...
ORIC Pharmaceuticals Appoints Ashraf Hanna, PhD, MD, as Chief Executive Officer, and Darcy Mootz, PhD, as Chief Business Officer
August 10, 2016 15:39 ET | ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, a privately-held oncology company focused on the discovery and development of drugs targeting...